Edward Marcus, MD
Ophthalmology · New York, NYNPI 1841451937
Payments from drug & device makers
Across 1,210 payments — averaging $152.66 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Regeneron Healthcare Solutions, Inc.$37K
- Alimera Sciences, Inc.$32K
- Astellas Pharma US Inc$26K
- Astellas Pharma Global Development$22K
- Regeneron$10K
- AbbVie$9K
- plus $49K from 25 others
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Regeneron Healthcare Solutions, Inc. | 144 | $37,321 |
| Alimera Sciences, Inc. | 132 | $31,704 |
| Astellas Pharma US Inc | 58 | $25,637 |
| Astellas Pharma Global Development | 15 | $21,583 |
| Regeneron | 2 | $9,855 |
| AbbVie(2 entities) | 121 | $9,253 |
| Mallinckrodt Hospital Products Inc. | 161 | $9,232 |
| Bausch & Lomb Americas Inc. | 81 | $7,494 |
| Novartis | 51 | $6,171 |
| Apellis Pharmaceuticals, Inc. | 61 | $5,857 |
| Eyepoint US, Inc. | 116 | $5,498 |
| Dutch Ophthalmic, USA | 7 | $3,331 |
| Novartis Pharma AG | 1 | $2,925 |
| ANI Pharmaceuticals, Inc. | 34 | $2,495 |
| Harrow Eye, LLC | 56 | $2,401 |
| Genentech USA, Inc. | 60 | $1,226 |
| Coherus Oncology, Inc. | 27 | $663 |
| Sandoz | 22 | $565 |
| Biotissue Holdings Inc. | 9 | $294 |
| Alcon | 4 | $287 |
| Mallinckrodt Enterprises LLC | 25 | $238 |
| Biogen | 9 | $228 |
| Rxsight Inc | 1 | $131 |
| Lensar, Inc. | 1 | $101 |
| Amgen | 4 | $72 |
| Sun Pharmaceutical Industries Inc. | 2 | $39 |
| Oyster Point Pharma, Inc. | 2 | $38 |
| Samsara Vision | 1 | $29 |
| Ocular Therapeutix, Inc. | 1 | $25 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 1 | $16 |
| Notal Vision, Inc. | 1 | $6 |
How this compares
$184,713 in reported general payments places this provider in the 95th percentile of 1,587 ophthalmology providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other ophthalmology in New York
- Douglas JabsNew York$24.3M
- Nathan RadcliffeNew York$2.4M
- Richard SpaideNew York$1.7M
- Jason SlakterNew York$1.2M
- David ChuNew York$1.2M
- Sharon KehNew York$941K
- Joshua YoungNew York$814K
- Joseph PanarelliNew York$704K
- Joshua KimNew York$677K
- Eric RosenbergNew York$526K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.